Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| - approved (en)
- investigational (en)
|
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Dacarbazine is subject to renal tubular secretion rather than glomerular filtration. In man, dacarbazine is extensively degraded. Besides unchanged dacarbazine, 5-aminoimidazole -4 carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine. (en)
|
http://linked.open.../drugbank/synonym
| - Dacarbazine (en)
- DTIE (en)
- ICDMT (en)
- Imidazole Carboxamide (en)
- 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (en)
- DIC (en)
- 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide (en)
- 4-(Dimethyltriazeno)imidazole-5-carboxamide (en)
- 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide (en)
- 5-(Dimethyltriazeno)imidazole-4-carboxamide (en)
- Biocarbazine (en)
- DTCI (en)
- Dacarbazin (en)
- Dacarbazina (en)
- Dacarbazinum (en)
- Dtic-dome (tn) (en)
- HSDB 3219 (en)
- NCI-C04717 (en)
- NSC 45388 (en)
- NSC-45388 (en)
- 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide (en)
- Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)- (en)
|
http://linked.open...drugbank/toxicity
| - LD<sub>50</sub>=350mg/kg (orally in mice) (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...nk/proteinBinding
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Erratic, slow and incomplete (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |